Prohibiting a 340B manufacturer from taking certain direct or indirect actions to limit or restrict the acquisition or delivery of a 340B drug; making a violation of the Act an unfair, abusive, or deceptive trade practice within the meaning of the Consumer Protection Act; and requiring the Maryland Prescription Drug Affordability Board to conduct a study of the 340B Program and report its findings and recommendations to certain committees of the General Assembly by July 1, 2026.